http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2009101384-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-172 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-118 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate | 2007-06-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2010-07-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2009101384-A |
| titleOfInvention | ALZHEIMER'S DISEASE PROGRESS BIOMARKERS |
| abstract | 1. The use of an agent that modulates leucine-rich repeat kinase 2 (BLPK2-modulating agent), to obtain a medicine for the treatment of Alzheimer's disease in patients in a selected population, the patient population is selected by the presence of polymorphisms in the gene of leucine-rich repeat kinase 2 (BLPK2), which are indicative of the progression of mild cognitive impairment (LSC) to Alzheimer's disease. ! 2. The use according to claim 1, in which BLPK2-modulating agent is a heterocyclic compound. ! 3. The use according to claim 1, in which the treatment of Alzheimer's disease slows down the progression of a patient with mild cognitive impairment (LSC) to Alzheimer's disease. ! 4. The use according to claim 1, in which the treatment of Alzheimer's disease slows down the progression in a patient of a moderate stage of Alzheimer's disease to a severe stage of Alzheimer's disease. ! 5. The use according to claim 1, in which the polymorphism in the BLPK2 gene is selected from the group consisting of T1602S and T2352. ! 6. The use according to claim 5, in which the T1602S locus in the patient has the TT genotype (Thr / Thr). ! 7. The use according to claim 5, in which the T2352 locus in the patient has a CC genotype (Thr / Thr). ! 8. A method for predicting the progression of Alzheimer's disease in a subject, comprising the steps! (a) obtaining a sample of tissue of the subject,! (b) analyzing the sample for the presence of genetic polymorphism indicating a progression in a subject of mild cognitive impairment (LSC) to Alzheimer's disease, the presence of a genetic polymorphism in a subject indicating progression in a subject of mild cognitive impairment to Alzheimer's predicts that the subject has an increased risk of progress� |
| priorityDate | 2006-06-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 24.